-
Mashup Score: 0Most US adults estimated to have subclinical cardiovascular-kidney-metabolic syndrome - 2 hour(s) ago
More than 70% of the overall U.S. population is estimated to have subclinical cardiovascular-kidney-metabolic syndrome, according to a research letter published in the Journal of the American College of Cardiology. “In light of emerging data on the CVD risk conferred by comorbidity risk factors, the American Heart Association introduced the framework for the cardiovascular-kidney-metabolic
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 2FDA approves novel bioresorbable scaffold for treating chronic limb-threatening ischemia - 3 hour(s) ago
Abbott announced the FDA has approved its novel below-the-knee, bioresorbable, drug-eluting scaffold for people with chronic limb-threatening ischemia. The approval is based on the results of the LIFE-BTK trial, presented at Transcatheter Cardiovascular Therapeutics 2023, which compared the scaffold (Esprit BTK everolimus-eluting resorbable scaffold system) with conventional balloon angioplasty
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 8Most US adults estimated to have subclinical cardiovascular-kidney-metabolic syndrome - 14 hour(s) ago
More than 70% of the overall U.S. population is estimated to have subclinical cardiovascular-kidney-metabolic syndrome, according to a research letter published in the Journal of the American College of Cardiology. “In light of emerging data on the CVD risk conferred by comorbidity risk factors, the American Heart Association introduced the framework for the cardiovascular-kidney-metabolic
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 3FDA approves novel bioresorbable scaffold for treating chronic limb-threatening ischemia - 16 hour(s) ago
Abbott announced the FDA has approved its novel below-the-knee, bioresorbable, drug-eluting scaffold for people with chronic limb-threatening ischemia. The approval is based on the results of the LIFE-BTK trial, presented at Transcatheter Cardiovascular Therapeutics 2023, which compared the scaffold (Esprit BTK everolimus-eluting resorbable scaffold system) with conventional balloon angioplasty
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 8Most US adults estimated to have subclinical cardiovascular-kidney-metabolic syndrome - 18 hour(s) ago
More than 70% of the overall U.S. population is estimated to have subclinical cardiovascular-kidney-metabolic syndrome, according to a research letter published in the Journal of the American College of Cardiology. “In light of emerging data on the CVD risk conferred by comorbidity risk factors, the American Heart Association introduced the framework for the cardiovascular-kidney-metabolic
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 3FDA approves novel bioresorbable scaffold for treating chronic limb-threatening ischemia - 20 hour(s) ago
Abbott announced the FDA has approved its novel below-the-knee, bioresorbable, drug-eluting scaffold for people with chronic limb-threatening ischemia. The approval is based on the results of the LIFE-BTK trial, presented at Transcatheter Cardiovascular Therapeutics 2023, which compared the scaffold (Esprit BTK everolimus-eluting resorbable scaffold system) with conventional balloon angioplasty
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 23CV Board – Building a New Board for Cardiovascular Medicine - 3 day(s) ago
Other cardiovascular organizations, including the American Heart Association (AHA), have applauded the vision and have collaborated in the development of the application. Formal support from the AHA is pending, dependent on official review and consideration by the organization’s Board of Directors at its next scheduled meeting. The field of cardiology has evolved as its own distinct specialty, separate from internal medicine. Having a separate and distinct medical Board is best for cardiovascular professio
Source: cvboard.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 1
Progress has been made in the creation of a new independent Board of Cardiovascular Medicine under the American Board of Medical Specialties, several cardiology societies announced.The American Board of Medical Specialties (ABMS) Advisory Board on Specialty Board Development has announced a 90-day comment period on the subject, and the cardiology societies — the American College of
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 1
Progress has been made in the creation of a new independent Board of Cardiovascular Medicine under the American Board of Medical Specialties, several cardiology societies announced.The American Board of Medical Specialties (ABMS) Advisory Board on Specialty Board Development has announced a 90-day comment period on the subject, and the cardiology societies — the American College of
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 1
Progress has been made in the creation of a new independent Board of Cardiovascular Medicine under the American Board of Medical Specialties, several cardiology societies announced.The American Board of Medical Specialties (ABMS) Advisory Board on Specialty Board Development has announced a 90-day comment period on the subject, and the cardiology societies — the American College of
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
More than 70% of the overall U.S. population is estimated to have subclinical cardiovascular-kidney-metabolic syndrome @ACCinTouch @Nephronline @EndocrineToday @GoHealio #Cardiotwitter @BCM_CVRI Read more👇 https://t.co/iL4LqODoqj